Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Community-based sofosbuvir + daclatasvir treatment for hepatitis C in people who inject drugs
IRCT20170213032547N1Phase 3Completed
- Sponsor
- Kerman University of Medical Sciences
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of sofosbuvir and daclatasvir in hepatitis C virus infection, sponsored by Kerman University of Medical Sciences. Primary endpoints: Treatment uptake, Treatment adherence and 1 more. Started Jun 2018; status: completed.
02
Drugs
sofosbuvirdaclatasvir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on IRCT20170213032547N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20170213032547N1.